Patents by Inventor Andrew Nunns
Andrew Nunns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11730792Abstract: The present invention relates to methods of treating or preventing AIBD.Type: GrantFiled: April 20, 2018Date of Patent: August 22, 2023Assignee: Volution Immuno Pharmaceuticals SAInventors: Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
-
Publication number: 20230002456Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.Type: ApplicationFiled: November 18, 2021Publication date: January 5, 2023Applicant: Volution Immuno Pharmaceuticals SAInventor: Miles Andrew Nunn
-
Publication number: 20220363726Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.Type: ApplicationFiled: January 5, 2022Publication date: November 17, 2022Applicant: VOLUTION IMMUNO PHARMACEUTICALS SAInventor: Miles Andrew Nunn
-
Patent number: 11214602Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.Type: GrantFiled: April 20, 2018Date of Patent: January 4, 2022Assignee: Volution Immuno Pharmaceuticals, SAInventor: Miles Andrew Nunn
-
Publication number: 20210171588Abstract: Methods of treating neuropathic pain are provided. In particular, the invention provides a method for treating neuropathic pain related mechanical hypersensitivity (allodynia and hyperalgesia) and peripheral neuropathic pain.Type: ApplicationFiled: December 7, 2018Publication date: June 10, 2021Applicant: Volution Immuno Pharmaceuticals SAInventors: Paul Louis Chazot, Miles Andrew Nunn, Ilona Genowefa Obara
-
Publication number: 20200385434Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.Type: ApplicationFiled: April 20, 2018Publication date: December 10, 2020Applicant: VOLUTION IMMUNO PHARMACEUTICALS SAInventor: Miles Andrew Nunn
-
Publication number: 20200113971Abstract: The present invention relates to methods of treating or preventing AIBD.Type: ApplicationFiled: April 20, 2018Publication date: April 16, 2020Applicant: VOLUTION IMMUNO PHARMACEUTICALS SAInventors: Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
-
Publication number: 20180127472Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.Type: ApplicationFiled: August 17, 2017Publication date: May 10, 2018Applicant: VOLUTION IMMUNO PHARMACEUTICALS SAInventor: Miles Andrew Nunn
-
Patent number: 9834585Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.Type: GrantFiled: February 18, 2015Date of Patent: December 5, 2017Assignee: Volution Immuni Pharmaceuticals SAInventor: Miles Andrew Nunn
-
Publication number: 20160096870Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.Type: ApplicationFiled: February 18, 2015Publication date: April 7, 2016Inventor: Miles Andrew NUNN
-
Patent number: 8993264Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.Type: GrantFiled: February 7, 2011Date of Patent: March 31, 2015Assignee: Volution Immuno Pharmaceuticals SAInventor: Miles Andrew Nunn
-
Publication number: 20110263482Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.Type: ApplicationFiled: February 7, 2011Publication date: October 27, 2011Inventor: Miles Andrew Nunn
-
Patent number: 7914986Abstract: A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions.Type: GrantFiled: May 19, 2005Date of Patent: March 29, 2011Assignee: Amplion LimitedInventor: Miles Andrew Nunn
-
Patent number: 7884188Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.Type: GrantFiled: June 2, 2004Date of Patent: February 8, 2011Assignee: Varleigh Immuno Pharmaceuticals (VIP) LtdInventor: Miles Andrew Nunn
-
Publication number: 20090311672Abstract: A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions.Type: ApplicationFiled: May 19, 2005Publication date: December 17, 2009Inventor: Miles Andrew Nunn
-
Patent number: 6295554Abstract: A system and method for communicating with a cable modem having an RF interface for downstream data and a PSTN interface for upstream data. The system uses a cable modem driver that receives commands for sending and receiving data. The cable modem driver interfaces to the RF interface to receive downstream data. The cable modem driver interfaces to an inner protocol driver to redirect data to a standard modem driver. The inner protocol driver sends the data to the modem driver and the modem driver sends the data over the PSTN connection.Type: GrantFiled: May 27, 1998Date of Patent: September 25, 2001Assignee: 3Com CorporationInventors: Baris Karadogan, Andrew Nunns, Philip Thomas Robinson